MTOR and renal cell carcinoma: Furthermore, it has been demonstrated that the mammalian target of rapamycin (mTOR) pathway, which plays a role in the control of cell proliferation in response to hypoxia, is considerably elevated in RCC (Rausch et al., 2019).